Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 21

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 21
---
 broad discretion
over the use of the net proceeds from the sale of the Common Stock
offered by this prospectus supplement and the
accompanying prospectus. We
currently intend to use the net proceeds, if
any, from the sale of the Common Stock offered
hereby for general corporate purposes, including working capital, operating
expenses, and capital expenditures. We may also
use a portion of the net proceeds to acquire or invest
in businesses and products that are complementary
to our own, although we have no current plans, commitments or agreements
with respect to any acquisitions as of the date
of this prospectus supplement. We
intend to invest the net proceeds to us from the sale
of the Common Stock offered hereby that are not used
as described above in short-term, investment-grade,
interest-bearing instruments.

<div align='center'>S-13

DIVIDEND POLICY</div>

Wehave never paid any cash dividends on our capital stock
and do not anticipate paying any cash dividends on our Common Stock
in the foreseeable future. We intend to retain
future earnings to fund ongoing operations and
future capital requirements. Any future determination
to pay cash dividends will be at the discretion
of our board of directors and will be dependent upon a number of factors, including future
earnings, our financial condition,
results of operations, capital requirements and
such other factors as the board of directors deems relevant.

<div align='center'>S-14

DILUTION</div>

If you purchase our Common Stock
in this offering, your ownership interest will
be immediately diluted to
the extent of the difference between
the price per share you pay and the net tangible
book value per share
of our Common Stock immediately after this offering.
Net tangible book value per share is determined by dividing the number of shares of Common
Stock outstanding as of September 30, 2025 by our total tangible assets
less total liabilities.

Our net tangible
book value as of September 30, 2025was approximately $(19.2) million, or $(0.83) per share,
based on 23,178,116 of our Common Stock outstanding
as of that date.*

After giving effect
to the sale of 8,933,455 shares of Common
Stock by us at an assumed offering price of $1.31
per share, the last reported sale price of our
Common Stock on Nasdaq on December 1, 2025, for
aggregate